Literature DB >> 6285702

Effect of acyclovir treatment on acute and chronic murine cytomegalovirus infection.

L A Glasgow, J T Richards, E R Kern.   

Abstract

Murine cytomegalovirus (MCMV) is inhibited in vitro by 1 to 2 microM acyclovir. Therapy of a systemic MCMV infection in weanling mice with acyclovir was only minimally effective when drug was administered intraperitoneally, while oral administration by addition of acyclovir to the drinking water was highly efficacious in mice with disseminated MCMV. Effective therapy was characterized by reduction of virus titers in lung, liver, spleen, and kidney. In mice chronically infected with MCMV, treatment for 30 days with oral acyclovir eliminated or reduced virus titers in all target organs except the salivary gland. Therapeutic efficacy in this model infection using oral administration of acyclovir could be correlated with the achievement of acyclovir levels in the plasma of experimental animals two to 10 times greater than the mean inhibitory concentration for MCMV in vitro throughout treatment. The lack of efficacy observed when drug was administered intraperitoneally was associated with acyclovir levels exceeding 1 microM for one to three hours after each dose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285702     DOI: 10.1016/0002-9343(82)90078-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Novel method for evaluating antiviral drugs against human cytomegalovirus in mice.

Authors:  L B Allen; S X Li; G Arnett; B Toyer; W M Shannon; M G Hollingshead
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

3.  Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.

Authors:  Gregory K Hong; Margaret L Gulley; Wen-Hai Feng; Henri-Jacques Delecluse; Elizabeth Holley-Guthrie; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine.

Authors:  J D Shanley; J Morningstar; M C Jordan
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.

Authors:  Mark N Prichard; Earl R Kern; Caroll B Hartline; E Randall Lanier; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

6.  Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.

Authors:  Earl R Kern; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

8.  Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection.

Authors:  Mark Beswick; Annette Pachnio; Sarah N Lauder; Clive Sweet; Paul A Moss
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.